The add-on payment “will be based on 65 percent of the per patient anticipated hospital cost achieved … up to a potential maximum of approximately $9,800,” CEO Laura Francis said during SI-Bone’s first-quarter earnings call, transcribed by Seeking Alpha.
Once the NTAP proposal is finalized, and if iFuse Bedrock Granite receives FDA clearance, the device will be available for additional Medicare payment in the hospital inpatient setting as part of multisegment spinal fusions, Ms. Francis said.
CMS uses the program to accelerate the adoption of innovative devices meeting certain cost and clinical improvement criteria after FDA approval.
“We believe the benefits of iFuse Granite’s differentiated technology, the seamless surgeon workflow integration and potential for incremental reimbursement, puts us in a strong competitive position,” Ms. Francis said. “It will allow us to accelerate our growth in an attractive, $250 million adjacent adult deformity market.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.